TWI BIOTECHNOLOGY. INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA) 2023-06-02 15:51
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA 2020-05-07 14:06
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy 2018-11-15 17:16
TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa 2018-02-26 16:58
TWi Biotechnology Inc. Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting 2017-11-01 17:05
1